Poder del músculo esquelético  en la salud y enfermedad

Sandra Marcela Mahecha

doi:10.35454/rncm.v4n4.288

Autores/as

Sandra Marcela Mahecha Clínica MEDS

DOI:

https://doi.org/10.35454/rncm.v4n4.288

Palabras clave:

Miocinas, Salud, Ejercicio, Músculo esquelético

Resumen

Las evidencias científicas son contundentes en mostrar que la inactividad física y el comportamiento sedentario tienen efectos perjudiciales en el músculo esquelético, las arterias, el miocardio y las mitocondrias, lo que aumenta el riesgo de enfermedades cardiovasculares, metabólicas, cáncer y, por tanto, la mortalidad prematura. El objetivo de esta revisión es describir los mecanismos fisiológicos de las miocinas liberadas por la contracción del músculo esquelético con el ejercicio físico y la aplicación clínica en la salud y enfermedad de niños y adultos.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Defrees DN, Bailey J. Irritable Bowel Syndrome: Epidemiology, Pathophysiology, Diagnosis, and Treatment. Prim Care. 2017;44(4):655-71. doi: 10.1016/j.pop.2017.07.009

Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908-17. doi: 10.1016/S2468-1253(20)30217-X

Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: A clinical review. JAMA. 2015;313(9):949-58. doi: 10.1001/jama.2015.0954

Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;S0016-5085(6)00222-5. doi: 10.1053/j.gastro.2016.02.031

López-Colombo A, Morgan D, Bravo-González D, Montiel-Jarquín A, Méndez-Martínez S, Schmulson M. The epidemiology of functional gastrointestinal disorders in Mexico: a population-based study. Gastroenterol Res Pract. 2012;2012:606174. doi: 10.1155/2012/606174

Diagnóstico y tratamiento del intestino irritable en el adulto [Internet]. México: CENETEC; 2015 [consultado el 20 de abril de 2021]. Disponible en: https://www.imss.gob.mx/sites/all/statics/guiasclinicas/042GRR.pdf

Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, et al. Irritable bowel syndrome. Nat Rev Dis Primers. 2016;2:16014. doi: 10.1038/nrdp.2016.14

Hellström PM. Pathophysiology of the irritable bowel syndrome - Reflections of today. Best Pract Res Clin Gastroenterol. 2019;40-41:101620. doi: 10.1016/j.bpg.2019.05.007

Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123(6):2108-31. doi: 10.1053/gast.2002.37095

Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet. 2002;360(9332):555-64. doi: 10.1016/S0140-6736(02)09712-X

Matricon J, Meleine M, Gelot A, Piche T, Dapoigny M, Muller E, et al. Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther. 2012;36(11-12):1009-31. doi: 10.1111/apt.12080

Saha L. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(22):6759-73. doi:10.3748/wjg.v20.i22.6759

Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009;136(6):1979-88. doi: 10.1053/j.gastro.2009.02.074

De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut. 2004;53(10):1520-35. doi:10.1136/gut.2003.035568

Saberi-Firoozi M, Khademolhosseini F, Mehrabani D, Yousefi M, Salehi M, Heidary ST. Subjective lactose intolerance in apparently healthy adults in southern Iran: Is it related to irritable bowel syndrome? Indian J Med Sci. 2007;61(11):591-7. doi: 10.4103/0019-5359.37045

Makker J, Chilimuri S, Bella JN. Genetic epidemiology of irritable bowel syndrome. World J Gastroenterol. 2015;21(40):11353-61. doi: 10.3748/wjg.v21.i40.11353

Remes-Troche JM, Gómez-Escudero O, Nogueira-de Rojas JR, Carmona-Sánchez R, Pérez-Manauta J, López-Colombo A, et al. Tratamiento farmacológico del síndrome de intestino irritable: revisión técnica. Rev Gastroenterol Mex. 2010;75(1):42-66.

Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007;56(12):1770-98. doi: 10.1136/gut.2007.119446

Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A. Small intestinal bacterial overgrowth and irritable bowel syndrome-related symtoms: experience with Rifaximin. World J Gastroenterol. 2009;15(21):2628-31. doi: 10.3748/wjg.15.2628

Frissora CL, Cash BD. Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. Aliment Pharmacol Ther. 2007;25(11):1271-81. doi: 10.1111/j.1365-2036.2007.03313.x

Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101(2):326-33. doi: 10.1111/j.1572-0241.2006.00458.x

Sultan S, Malhotra A. Irritable bowel syndrome. Ann Intern Med. 2017;166(11): ITC81-96. doi: 10.7326/AITC201706060

Ramkumar D, Rao SSC. Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol. 2005;100(4):936-71. doi: 10.1111/j.1572-0241.2005.40925.x

Chapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013;108(9):1508-15. doi: 10.1038/ajg.2013.197

Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130(5):1480-91. doi: 10.1053/j.gastro.2005.11.061

McKenzie YA, Bowyer RK, Leach H, Gulia P, Horobin J, O’Sullivan NA, et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016;29(5):549-75. doi: 10.1111/jhn.12385

Van Tilburg MAL, Palsson OS, Levy RL, Feld AD, Turner MJ, Drossman DA, et al. Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO. BMC Complement Altern Med. 2008;8:46. doi: 10.1186/1472-6882-8-46

Camilleri M. Management options for irritable bowel syndrome. Mayo Clin Proc. 2018;93(12):1858-72. doi: 10.1016/j.mayocp.2018.04.032

Lea R, Whorwell PJ. The role of food intolerance in irritable bowel syndrome. Gastroenterol Clin North Am. 2005;34(2):247-55. doi: 10.1016/j.gtc.2005.02.005

Daley AJ, Grimmett C, Roberts L, Wilson S, Fatek M, Roalfe A, et al. The effects of exercise upon symptoms and quality of life in patients diagnosed with irritable bowel syndrome: a randomised controlled trial. Int J Sports Med. 2008;29(9):778-82. doi: 10.1055/s-2008-1038600

Van Lanen A-S, de Bree A, Greyling A. Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis. Eur J Nutr. 2021;60(6):3505-22. doi.org/10.1007/s00394-020-02473-0

Whelan K, Martin LD, Staudacher HM, Lomer MCE. The low FODMAP diet in the management of irritable bowel syndrome: an evidence-based review of FODMAP restriction, reintroduction and personalisation in clinical practice. J Hum Nutr Diet. 2018;31(2):239-55. doi: 10.1111/jhn.12530

Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. J Gastroenterol Hepatol. 2010;25(2):252-8. doi: 10.1111/j.1440-1746.2009.06149.x

Whigham L, Joyce T, Harper G, Irving PM, Staudacher HM, Whelan K, et al. Clinical effectiveness and economic costs of group versus one-to-one education for short-chain fermentable carbohydrate restriction (low FODMAP diet) in the management of irritable bowel syndrome. J Hum Nutr Diet. 2015;28(6):687-96. doi: 10.1111/jhn.12318

Staudacher HM, Lomer MCE, Anderson JL, Barrett JS, Muir JG, Irving PM, et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr. 2012;142(8):1510-8. doi: 10.3945/jn.112.159285

Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut. 2015;64(1):93-100. doi: 10.1136/gutjnl-2014-307264

Tuck C, Barrett J. Re-challenging FODMAPs: the low FODMAP diet phase two. J Gastroenterol Hepatol. 2017;32(Suppl 1):11-5. doi: 10.1111/jgh.13687

Probert HM, Gibson GR. Investigating the prebiotic and gas-generating effects of selected carbohydrates on the human colonic microflora. Lett Appl Microbiol. 2002;35(6):473-80. doi: 10.1046/j.1472-765x.2002.01223.x

Heizer WD, Southern S, McGovern S. The role of diet in symptoms of irritable bowel syndrome in adults: a narrative review. J Am Diet Assoc. 2009;109(7):1204-14. doi: 10.1016/j.jada.2009.04.012

Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ. 2008;337:a2313. doi: 10.1136/bmj.a2313

Manning LP, Yao CK, Biesiekierski JR. Therapy of IBS: Is a low FODMAP diet the answer? Front Psychiatry. 2020;11:865. doi: 10.3389/fpsyt.2020.00865

Paduano D, Cingolani A, Tanda E, Usai P. Effect of three diets (low-FODMAP, gluten-free and balanced) on Irritable Bowel Syndrome symptoms and health-related quality of life. Nutrients. 2019;11(7):1566. doi: 10.3390/nu11071566

Dieterich W, Zopf Y. Gluten and FODMAPS-Sense of a Restriction/When Is Restriction Necessary? Nutrients. 2019;11(8):1957. doi: 10.3390/nu11081957

Ford AC, Quigley EMM, Lacy BE, Lembo AJ, Saito YA, Schiller LR, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547-61. doi: 10.1038/ajg.2014.202

Valdovinos M, Montijo E, Abreu A, Heller S, González-Garay A, Bacarreza D, et al. Consenso mexicano sobre probióticos en gastroenterología. Rev Gastroenterol Mex. 2017;82(2):156-178. doi: 10.1016/j.rgmx.2016.08.004

Urquiaga I, Echeverría G, Dussaillant C, Rigotti A. Origin, components and mechanisms of action of the Mediterranean diet. Rev Med Chil. 2017;145(1):85-95. doi: 10.4067/S0034-98872017000100012

Tabla orientativa. Alimentos con y sin gluten. [Internet]. Associació Celíacs de Catalunya [consultado el 20 de julio de 2021]. Disponible en: https://www.celiacscatalunya.org/pdfs/apto_no_apto.pdf